EntryPoint Capital LLC Purchases 1,633 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

EntryPoint Capital LLC lifted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 58.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,440 shares of the medical instruments supplier’s stock after buying an additional 1,633 shares during the quarter. EntryPoint Capital LLC’s holdings in LeMaitre Vascular were worth $409,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of LMAT. Smartleaf Asset Management LLC raised its stake in LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC increased its holdings in shares of LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 117 shares during the period. KBC Group NV raised its position in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 410 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of LeMaitre Vascular in the fourth quarter valued at approximately $150,000. Finally, SG Americas Securities LLC acquired a new stake in LeMaitre Vascular during the fourth quarter worth approximately $158,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Down 1.2 %

Shares of NASDAQ LMAT opened at $85.08 on Wednesday. The company has a market capitalization of $1.92 billion, a PE ratio of 46.49, a P/E/G ratio of 2.22 and a beta of 0.89. The firm has a fifty day simple moving average of $93.94 and a 200 day simple moving average of $94.48. LeMaitre Vascular, Inc. has a twelve month low of $62.39 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. The company had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.94%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date is Thursday, March 13th. LeMaitre Vascular’s payout ratio is presently 41.24%.

Insider Activity at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.79% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

LMAT has been the subject of a number of recent analyst reports. Lake Street Capital upped their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.